Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes
about
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical EvidencePancreatic regulation of glucose homeostasisGIP and GLP-1, the two incretin hormones: Similarities and differencesGIP contributes to islet trihormonal abnormalities in type 2 diabetes.Adaptive selection of an incretin gene in Eurasian populations.GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetesDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study.Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesRole of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery.The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women.Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.Diabetes and altered glucose metabolism with aging.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill.Does GLP-1 suppress its own basal secretion?Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.Molecular mechanisms underlying nutrient detection by incretin-secreting cells.Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders.The alpha-cell as target for type 2 diabetes therapy.Treating the obese diabetic.Direct cardiovascular effects of glucagon like peptide-1.The regulation of pre- and post-maturational plasticity of mammalian islet cell mass.Glucagon and type 2 diabetes: the return of the alpha cell.Islet α cells and glucagon--critical regulators of energy homeostasis.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.The New Biology and Pharmacology of Glucagon.Gut: A key player in the pathogenesis of type 2 diabetes?Preliminary study characterizing the use of sitagliptin for glycemic control in healthy Beagle dogs with normal gluco-homeostasis.Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates.Changes of blood glucose and gastrointestinal hormones 4 months after Roux-en-Y gastric bypass surgery in Chinese obese type 2 diabetes patients with lower body mass index.Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes.Insulin-like growth factor-1 is a negative modulator of glucagon secretion.The evolving world of GLP-1 agonist therapies for type 2 diabetes.Resistant starch intake at breakfast affects postprandial responses in type 2 diabetics and enhances the glucose-dependent insulinotropic polypeptide--insulin relationship following a second meal.
P2860
Q26739999-D38EE0FE-00C0-4C0D-B589-7082D665DD29Q26766485-7F587FE3-3BF6-477E-8DEB-52C7CD5485E8Q33609502-6F2A7683-888E-4B4F-B2EA-D3C38CC482DEQ33837142-2A1D0690-44AF-4068-9287-7C2BE534412BQ34452263-AAC3B344-B51C-442E-B6A9-B731179C4A41Q34718860-165F7B9E-64C3-45B8-A262-FDAE20A33352Q35026483-4662A68A-4FF9-40E2-92B3-D44DAE3FC990Q35122108-78E4A2ED-9100-4D37-A62F-40F7DE6F7529Q35690970-600CF670-2D1C-44A4-A393-225DFF8E1ED3Q35909303-5F45CCCC-F4C5-4236-9587-C433ED4E89E7Q35963032-3FF792E5-BB13-435E-B404-B95FFDAEDAD5Q36182540-C58B1491-526D-4235-8DB3-A6F38E07BAB0Q36317203-92186E6B-B259-44F0-817D-2A0A4DB7D8F4Q36503839-EDBAFC43-19E8-46FF-A6ED-F641A78AA6EEQ36875300-4856531C-1CE3-477C-AA48-274FF838EDF0Q37193295-8A7DDC25-D32C-4EC2-98AC-E232DD45893CQ37193583-241DF2C7-0FA7-48DD-93A5-03C685796564Q37517436-01FAEE2D-EA60-4085-9AFD-9B80572796DEQ37613876-56991A73-56E3-4F77-8E61-14E6811F9518Q37702790-026AA01D-EA2B-4DE9-8BDA-77310EE61E24Q37825941-9A90F1FB-CA5E-4AAF-82A5-43D0171FBDE0Q37911549-F2EF41FF-66A5-470B-9D00-B6849BB2F57FQ37977335-38A54AE0-8EAD-4212-8F69-D8256D968943Q38087696-B2D51003-779E-4871-BB7F-CA0A4452C67AQ38132470-27423CDF-404A-4D7F-A2E1-3A9FB68231CEQ38211528-08F30446-237E-4455-93B1-284B5B56F8AAQ38262673-40FA1251-0339-43B3-A2FD-791FEE588325Q38409880-8EE63A6E-A592-4CC7-9CC4-797148F1BB00Q38527885-AE641C38-AB98-4E65-9EB9-E09371451F9AQ38830154-03AC611A-8C4E-43FD-8D6D-DD2F4EF18502Q38919742-5E1063D7-EEDE-4440-8375-7B62DFAAAA62Q39021924-C1DE3163-9775-4ABE-9773-731A0AE15BB3Q39175579-A9DFE9DA-BD71-4D7F-9AEC-6588FCCAB121Q39221120-82175122-D8E9-4E6D-AD7D-D7F2E6247C8DQ39485182-F8627F6E-4EC1-4751-9E9E-4472C64D8BD3Q39553929-101053B5-8A95-44DC-AB7F-08B5AD1F54ECQ39816226-526E90F9-C8A6-4713-8855-1EFCB4EFE6A2Q41612986-F2C0DFBB-5467-4555-BEC7-75544EA03D91Q42054096-7CCE8EE0-8E6E-4A66-A1F2-FBD212745F21Q45970525-2C02460A-6DF3-48CC-8B9C-8E499AC27818
P2860
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Exogenous glucose-dependent in ...... perglycemia in type 2 diabetes
@en
Exogenous glucose-dependent in ...... erglycemia in type 2 diabetes.
@nl
type
label
Exogenous glucose-dependent in ...... perglycemia in type 2 diabetes
@en
Exogenous glucose-dependent in ...... erglycemia in type 2 diabetes.
@nl
prefLabel
Exogenous glucose-dependent in ...... perglycemia in type 2 diabetes
@en
Exogenous glucose-dependent in ...... erglycemia in type 2 diabetes.
@nl
P2093
P2860
P921
P356
P1433
P1476
Exogenous glucose-dependent in ...... perglycemia in type 2 diabetes
@en
P2093
Chee W Chia
Cornelia P Charles
Denise L Melvin
Hee Seung Kim
Olga D Carlson
Yu-Kyong Shin
P2860
P304
P356
10.2337/DB08-0958
P407
P577
2009-03-10T00:00:00Z